Amy Schulman

What if we stopped trying to change the people, and we changed the pill instead?

Share This Talk

Have a suggestion for The Hive?
Submit a Nomination Today

About Amy Schulman

Amy W. Schulman is the Chief Executive Officer of Lyndra, Inc. In 2014, she joined Polaris Partners’ Boston office, simultaneously assuming the role of CEO of Arsia Therapeutics, a Polaris-backed company which was acquired by Eagle Pharmaceuticals in November 2016. In July 2015, Amy co-founded Lyndra, where she is CEO. Amy is the recipient of numerous awards and distinctions including: Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, Fortune Magazine’s 2013 50 Most Powerful Women in Business, The American Lawyer’s 2013 Top 50 Innovators, and The National Law Journal’s 2013 100 Most Influential Lawyers in America. She is a member of Harvard Business School’s Faculty where she serves as a Senior Lecturer and teaches legal and corporate accountability. A Phi Beta Kappa graduate of Wesleyan University, Amy earned her JD from Yale Law School in 1989. She serves as the Executive Chair of SQZ Biotech and Suono Bio and is director of Alnylam Pharmaceuticals and Ironwood Pharmaceuticals. In addition, Amy serves as a director of Blue Buffalo and the Whitehead Institute.

Find out more

About This Idea

According to Lyndra CEO Amy Schulman, “We spend over 300 billion dollars in avoidable healthcare costs because we don’t take the medication that is prescribed for us.” Instead of trying to find new ways to remind people to take their medications, Amy and the Lyndra team have set out to change the pill itself. Tune in to Amy’s 2017 TEDMED Hive Talk to learn how Lynda’s ultra long-acting oral drug delivery platform reduces the frequency of how often a medication must be taken and helps to boost patient adherence.

Find out more

More Talks from the Hive

These talks are all a part of special session at TEDMED, called "Audacious" where we invite our innovators to take the stage and share the central idea they are working on, in short 2-minute talks. These talks are creatively grouped by 4 mini-segments, that serves as a creative link between each talk. To find out more visit The Hive page.